SYnAbs and Volition ink strategic deal on epigenetic modifications targeting -- MEDICA - World Forum for Medicine

24.09.2020

SYnAbs S.A.

SYnAbs and Volition ink strategic deal on epigenetic modifications targeting

SYnabs will develop monoclonal antibodies of mice, rats, and guinea pigs against 16 different post-translational modifications on histones including methylation, acetylation, phosphorylation, and mutations.

Exhibitor Data Sheet